[go: up one dir, main page]

EA200801852A1 - Индолопиридины в качестве модуляторов кинезина eg5 - Google Patents

Индолопиридины в качестве модуляторов кинезина eg5

Info

Publication number
EA200801852A1
EA200801852A1 EA200801852A EA200801852A EA200801852A1 EA 200801852 A1 EA200801852 A1 EA 200801852A1 EA 200801852 A EA200801852 A EA 200801852A EA 200801852 A EA200801852 A EA 200801852A EA 200801852 A1 EA200801852 A1 EA 200801852A1
Authority
EA
Eurasian Patent Office
Prior art keywords
indolopiridine
kinesine
modulators
compounds
antiproliferative
Prior art date
Application number
EA200801852A
Other languages
English (en)
Other versions
EA015151B1 (ru
Inventor
Маттиас Веннеманн
Томас Бер
Йюрген Браунгер
Астрид Зиммерманн
Фолькер Гекелер
Original Assignee
4ЭсЦэ АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4ЭсЦэ АГ filed Critical 4ЭсЦэ АГ
Publication of EA200801852A1 publication Critical patent/EA200801852A1/ru
Publication of EA015151B1 publication Critical patent/EA015151B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Соединения конкретной формулы I, где R1, R2, R3, R4, R5 и R6 имеют значения, указанные в описании, являются эффективными соединениями, обладающими антипролиферативной и/или апоптоз-индуцирующей активностью.
EA200801852A 2006-02-22 2007-02-21 Индолопиридины в качестве модуляторов кинезина eg5 EA015151B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06110298 2006-02-22
PCT/EP2007/051691 WO2007096395A1 (en) 2006-02-22 2007-02-21 Indolopyridines as eg5 kinesin modulators

Publications (2)

Publication Number Publication Date
EA200801852A1 true EA200801852A1 (ru) 2009-04-28
EA015151B1 EA015151B1 (ru) 2011-06-30

Family

ID=36694150

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801852A EA015151B1 (ru) 2006-02-22 2007-02-21 Индолопиридины в качестве модуляторов кинезина eg5

Country Status (14)

Country Link
US (1) US20090246169A1 (ru)
EP (1) EP1994033A1 (ru)
JP (1) JP2009527534A (ru)
KR (1) KR20080103977A (ru)
CN (1) CN101389629A (ru)
AU (1) AU2007217562A1 (ru)
BR (1) BRPI0710073A2 (ru)
CA (1) CA2643665A1 (ru)
EA (1) EA015151B1 (ru)
IL (1) IL193624A0 (ru)
MX (1) MX2008010799A (ru)
NZ (1) NZ571356A (ru)
WO (1) WO2007096395A1 (ru)
ZA (1) ZA200808071B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
DE602004011340T2 (de) 2003-05-20 2008-11-06 Bayer Healthcare Llc Diaryl-harnstoffe mit kinasehemmender wirkung
ATE517885T1 (de) 2004-04-30 2011-08-15 Bayer Healthcare Llc Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
CA2576619A1 (en) 2004-08-18 2006-02-23 Altana Pharma Ag Benzothienopyridines for use as inhibitors of eg5 kinesin
EP2522396A1 (en) 2005-02-03 2012-11-14 TopoTarget UK Limited Combination therapies using HDAC inhibitors
BRPI0610128B1 (pt) 2005-05-13 2021-12-07 Topotarget Uk Limited Composição farmacêutica, e, uso de uma composição
JP5377968B2 (ja) 2005-11-10 2013-12-25 トポターゲット ユーケー リミテッド 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ(hdac)阻害剤
EP2033962A1 (en) * 2007-08-22 2009-03-11 4Sc Ag Tetracyclic indolopyridines as EG5 inhibitors
CN101868446A (zh) * 2007-09-25 2010-10-20 托波塔吉特英国有限公司 某些异羟肟酸化合物的合成方法
MX2010009642A (es) * 2008-03-07 2010-09-22 Topotarget As Metodos de tratamiento utilizando infusion continua prolongada de belinostat.
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
CN102188698B (zh) * 2010-03-08 2014-10-01 上海南方模式生物科技发展有限公司 核糖核酸酶和青蒿素的联用
WO2012009097A1 (en) 2010-06-17 2012-01-19 Cytokinetics, Inc. Methods of treating lung disease
IN2013KO01293A (ru) * 2013-11-13 2015-05-15 Univ Calcutta
GB202207348D0 (en) 2022-05-19 2022-07-06 Cypralis Ltd Macrocyclic compounds and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890933B1 (en) * 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
AU2002310099A1 (en) * 2001-05-22 2002-12-03 President And Fellows Of Harvard College Identification of anti-protozoal agents
DE60220422T2 (de) * 2001-09-19 2008-02-07 Pharmacia Corp. Substituierte pyrazol-verbindungen zur behandlung von entzündungen
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US7307085B2 (en) * 2003-08-13 2007-12-11 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2576619A1 (en) * 2004-08-18 2006-02-23 Altana Pharma Ag Benzothienopyridines for use as inhibitors of eg5 kinesin

Also Published As

Publication number Publication date
CA2643665A1 (en) 2007-08-30
WO2007096395A1 (en) 2007-08-30
CN101389629A (zh) 2009-03-18
NZ571356A (en) 2010-08-27
EP1994033A1 (en) 2008-11-26
MX2008010799A (es) 2008-11-06
AU2007217562A1 (en) 2007-08-30
ZA200808071B (en) 2010-08-25
IL193624A0 (en) 2009-05-04
US20090246169A1 (en) 2009-10-01
EA015151B1 (ru) 2011-06-30
BRPI0710073A2 (pt) 2011-08-02
JP2009527534A (ja) 2009-07-30
KR20080103977A (ko) 2008-11-28

Similar Documents

Publication Publication Date Title
EA200801739A1 (ru) Индолопиридины в качестве модуляторов кинезина eg5
EA200801852A1 (ru) Индолопиридины в качестве модуляторов кинезина eg5
UA94412C2 (en) Glutamate aggrecanase inhibitors
BRPI0717266A2 (pt) Derivados de oxindol
EA200701840A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
MX2007001127A (es) Moduladores de pirrolo-piridina cinasa.
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
EA200702470A1 (ru) Производные пиррола в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
EA201100037A1 (ru) Органические соединения
EA201070451A1 (ru) Амидные соединения
EA200701467A1 (ru) Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
EP1850843A4 (en) ACTIVITY INHIBITORS OF AKT
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
ATE432272T1 (de) Aminophenylderivate als neue inhibitoren von histondeacetylase
EA201000566A1 (ru) Гетероциклические сетр ингибиторы
EA200601587A1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины
MA31889B1 (fr) N-phenyl -bipyrrolidine-urees substituees et utilisation therapeutique de celles-ci
ATE510821T1 (de) Sulfonylpyrrole als histondeacetylaseinhibitoren
BRPI0909333A2 (pt) derivado de espiroindolinona
EA200601568A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
EA200800070A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина
EA200700702A1 (ru) Аналоги локсапина и способы их применения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU